5 minOn June 23, 2026, Corxel Pharmaceuticals announced positive topline results from its U.S. Phase 2 clinical trial of CX11, an oral small molecule GLP-1 receptor agonist (GLP-1 RA). The data demonstrate that the drug achieved up to an 11.5% reduction in body weight after 36 weeks of treatment, while maintaining a favorable gastrointestinal (GI) tolerability profile and hepatic safety.
Clinical Highlights: 11.5% Weight Loss at 36 Weeks
The U.S. Phase 2 study (NCT07011797) enrolled 246 adults living with obesity (BMI ≥30 kg/m²) or who were overweight (BMI 27–30 kg/m²) with at least one weight-related comorbidity. Participants were randomized to receive once-daily oral doses of CX11 (120 mg, 160 mg, or 200 mg, with both slow and fast titration arms) or a placebo for 36 weeks.
Key clinical findings include:
-
Efficacy and Sustainability: At the 36-week mark, CX11 achieved weight loss of up to 11.5% in the U.S. obesity cohort. Notably, clinical curves indicated that weight reduction continued at a consistent and steady rate with no evidence of a plateau or slowing trajectory, suggesting that extended treatment could yield even greater benefits.
-
GI Tolerability: Gastrointestinal (GI) side effects, a common hurdle for GLP-1 therapy, were well-managed with CX11. Nausea rates ranged from 33% to 34%, while vomiting rates were kept markedly low at 12% to 16%. Rates for diarrhea (4–12%) and constipation (2–12%) were also within a manageable range. Most GI-related adverse events were mild to moderate, primarily occurring during the dose-escalation period and subsiding as patients entered the maintenance phase.
-
High Adherence: Reflecting the favorable tolerability profile, the overall treatment discontinuation rate due to GI-related adverse events was low, at just 5.0%, highlighting the drug's potential for superior patient adherence compared to existing GLP-1 therapies.
Global Evidence: Robust Safety Profile
These U.S. results are supported by data from the Phase 3 clinical program in China, executed by Corxel’s partner, Vincentage Pharma. The consistency between these datasets provides a strong evidentiary foundation for CX11’s global development.
The drug demonstrated an excellent hepatic safety profile, with no hepatic safety signals observed in either the U.S. Phase 2 trial or the Chinese Phase 3 study. To date, more than 1,500 participants have been studied across all CX11 clinical trials, with consistent results confirming a favorable safety profile, which serves as a vital safeguard for the upcoming global Phase 3 program.
Disrupting the Market: The "Breakthrough" of Oral Small Molecules
Cardiometabolic disease remains a leading cause of global mortality, accounting for over 30% of annual deaths. Despite the high efficacy of current GLP-1 treatments, widespread adoption is hampered by the inconvenience of subcutaneous injections, titration complexity, tolerability issues, and global supply constraints.
CX11, as an oral small molecule GLP-1 RA, addresses these limitations through:
-
Enhanced Convenience: A once-daily oral administration removes the barrier of injections and significantly lowers the threshold for therapy initiation, which is critical given that nearly 50% of patients with chronic conditions currently fail to adhere to prescribed regimens.
-
Comparable Efficacy: Clinical data confirm that CX11 can achieve weight reduction comparable to injectable GLP-1 RAs.
-
Scalability and Accessibility: As a small molecule, CX11 benefits from efficient manufacturing and cost-control advantages, positioning it to better address the surging global demand for weight management solutions.
Future Outlook: Advancing to Global Phase 3
"We are delighted with these positive U.S. Phase 2 results, which are consistent with the competitive profile established in the China Phase 3 program," said Bo Liang, MD, PhD, Chief Medical Officer of Corxel. "These datasets reinforce our confidence in CX11 and our conviction to offer patients around the world an effective, highly tolerable, and flexible treatment option."
Following these results, Corxel is moving to advance CX11 into pivotal global Phase 3 clinical trials. Beyond CX11, the company is actively developing a diversified cardiometabolic pipeline, including its internally discovered oral small molecule amylin receptor agonist, CX12, which is currently in preclinical development. These efforts underscore Corxel’s commitment to redefining treatment standards for patients globally.
